First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01728259|
Recruitment Status : Suspended (Temporarily enrollment suspension due to unknown cause of death of participant)
First Posted : November 19, 2012
Last Update Posted : April 7, 2017
|Condition or disease||Intervention/treatment||Phase|
|Light Chain Deposition Disease Primary Systemic Amyloidosis||Drug: pomalidomide Drug: bortezomib Drug: dexamethasone Other: Laboratory Biomarker Analysis||Phase 1|
I. Establish the maximum tolerated dose (MTD) of the combination of pomalidomide, bortezomib, and dexamethasone (PVD) to take forward in a subsequent phase 2 study.
I. Obtain a preliminary assessment of efficacy of PVD regimen as initial treatment of amyloid light-chain (AL) or light chain deposition disease (LCDD).
OUTLINE: This is a dose-escalation study of pomalidomide and bortezomib.
Patients receive pomalidomide orally (PO) on days 1-21; bortezomib intravenously (IV) on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at least every 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||36 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease|
|Study Start Date :||March 2013|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||June 2017|
Experimental: Treatment (pomalidomide, bortezomib, and dexamethasone)
Patients receive pomalidomide PO on days 1-21; bortezomib IV or SC on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Other Name: CC-4047Drug: bortezomib
Other Names:Drug: dexamethasone
Other Names:Other: Laboratory Biomarker Analysis
- Maximum tolerated dose defined as the dose level before 2 of 6 patients experience dose-limiting toxicity (DLT) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: 28 days ]
- Complete hematologic response rate (hCR) [ Time Frame: Up to 28 days ]Will be estimated and reported with 95% confidence intervals.
- Overall hematologic response rate (partial response [PR] + complete response [CR]) [ Time Frame: Up to 28 days ]
- Organ response rates (heart, liver, kidney) [ Time Frame: Up to 28 days ]Organ responses will be tabulated and reported for all patients with cardiac, renal, hepatic, and/or neurologic involvement by amyloidosis.
- Overall survival [ Time Frame: From date of registration to date of death, assessed up to 28 days ]Will be estimated and reported with 95% confidence interval.
- Progression free survival [ Time Frame: Up to 28 days ]Will be estimated and reported with 95% confidence interval.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01728259
|United States, Colorado|
|Colorado Blood Cancer Institute|
|Denver, Colorado, United States, 80218|
|United States, Massachusetts|
|Boston University School of Medicine|
|Boston, Massachusetts, United States, 02118-2393|
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201|
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27710|
|Princess Margaret Cancer Centre|
|Toronto, Ontario, Canada, M5G 2M9|
|Principal Investigator:||Jeffrey Zonder||Barbara Ann Karmanos Cancer Institute|